A Trial of Vigil for Participants With Ovarian Cancer (VITAL)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02346747 |
Recruitment Status :
Active, not recruiting
First Posted : January 27, 2015
Last Update Posted : May 10, 2024
|
Sponsor:
Gradalis, Inc.
Information provided by (Responsible Party):
Gradalis, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | December 2025 |
Estimated Study Completion Date : | December 2025 |
Publications of Results:
Other Publications:
Other Publications:
Senzer N, Barve M, Nemunaitis J, Kuhn J, Melnyk A, et al. (2013) Long Term Follow Up: Phase I Trial of "Bi-Shrnafurin/GMCSF DNA/Autologous Tumor Cell" Immunotherapy (FANG™) in Advanced Cancer. J Vaccines Vaccin 4:209. doi: 10.4172/2157-7560.1000209